NCR3LG1 and neoplasm: However, inhibiting ILC2s may be beneficial in the context of cancer, as highlighted by findings by Trabanelli et al. [19] In this study, tumor-derived PGD2 and B7-H6 activated and expanded ILC2s in the context of acute promyelocytic leukaemia.